Ascendis Pharma A/S (NASDAQ:ASND) Price Target Lowered to $180.00 at Oppenheimer

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price reduced by investment analysts at Oppenheimer from $190.00 to $180.00 in a research note issued on Friday,Benzinga reports. The firm presently has an "outperform" rating on the biotechnology company's stock. Oppenheimer's price objective points to a potential upside of 42.28% from the company's previous close.

Other research analysts also recently issued reports about the company. Bank of America raised their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Jefferies Financial Group raised their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a "buy" rating in a report on Tuesday, August 13th. Citigroup raised their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a report on Tuesday, September 17th. Wedbush reaffirmed an "outperform" rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday. Finally, StockNews.com cut Ascendis Pharma A/S from a "hold" rating to a "sell" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $191.77.

Ascendis Pharma A/S Trading Up 1.8 %

Shares of NASDAQ ASND traded up $2.23 during midday trading on Friday, hitting $126.51. The company's stock had a trading volume of 1,448,850 shares, compared to its average volume of 450,130. The business's 50 day moving average is $132.30 and its two-hundred day moving average is $132.70. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The firm has a market cap of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analysts' expectations of $94.74 million. On average, analysts predict that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds have recently modified their holdings of the stock. Westfield Capital Management Co. LP boosted its holdings in Ascendis Pharma A/S by 3.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock valued at $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after acquiring an additional 229,995 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock valued at $625,075,000 after acquiring an additional 267,881 shares during the last quarter. Capital International Investors grew its stake in shares of Ascendis Pharma A/S by 0.5% during the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company's stock valued at $331,261,000 after buying an additional 10,044 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock valued at $278,760,000 after buying an additional 155,971 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.